BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.
Argenx (ENXTBR:ARGX) Stock Faces Margin Compression As 32.3% Profitability Tests Bullish Narrative
ARGX: Q2 revenue up 60% YoY, VYVGART expands in MG/CIDP, pipeline and financials remain strong
ARGX: Q2 2026 delivered 60% sales growth and expanded VYVGART reach, with strong profit gains
argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billion
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
argenx SE GAAP EPS of $7.32 beats by $1.12, revenue of $1.52B beats by $90M
The Nasdaq Biotechnology Index fell 3% in a single session. Fulcrum Therapeutics dropped 51%. Abivax ADR declined 44%. To someone unfamiliar with biotech investing, these numbers look like a sector-wi...
